

August 10, 2018  
Carna Biosciences, Inc.

### **Sierra Oncology reports on the progress of SRA141**

Carna Biosciences announces that Sierra Oncology, Inc (British Columbia, Canada, Dr. Nick Glover, Ph.D., President and Chief Executive Officer, NASDAQ:SRRA) has reported on SRA141, a CDC7 inhibitor for treating Cancer that Carna out-licensed to Sierra in May 2016, in its second quarter results.

Sierra Oncology reported in its quarterly report (FORM10-K) disclosed on August 9 EST, “We have completed all gating preclinical research for SRA141 and plan to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) in the second half of 2018 in order to commence clinical trials with this drug candidate. Upon dosing of the first patient in the first Phase 1 clinical trial of SRA141, a milestone payment of \$4.0 million will be due to Carna Biosciences, Inc. (Carna), the licensor of this asset.”

Following the report from Sierra Oncology, Dr. Kohichiro Yoshino, President and CEO at Carna Biosciences said, “We are very pleased that the development of SRA141 by Sierra Oncology has progressed as planned and Sierra is expecting to submit an IND in the second half of 2018. We look forward to the initiation of clinical study of SRA141.”

For more information, please visit <https://www.sierraoncology.com/>.

Contact:  
Corporate Planning  
Carna Biosciences, Inc.  
TEL: +81-78-302-7075